EGFR and non-small cell lung carcinoma: Researchers also found that the co-treatment of erlotinib and Cur greatly increases the mortality of erlotinib-resistant cells due to the decreased expression of EGFR and repression of NF-κB activation in EGFR-mutant NSCLC cells [93].